Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Other Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - Net
Ratios

Dr Reddys Laboratories (RDY) Non-Current Receivables (2017 - 2025)

Dr Reddys Laboratories has reported Non-Current Receivables over the past 9 years, most recently at $21.0 million for Q1 2025.

  • For Q1 2025, Non-Current Receivables fell 53.03% year-over-year to $21.0 million; the TTM value through Mar 2025 reached $21.0 million, down 53.03%, while the annual FY2025 figure was $21.0 million, 53.33% down from the prior year.
  • Non-Current Receivables for Q1 2025 was $21.0 million at Dr Reddys Laboratories, down from $44.8 million in the prior quarter.
  • Over five years, Non-Current Receivables peaked at $44.8 million in Q1 2024 and troughed at $718150.0 in Q1 2022.
  • A 5-year average of $20.2 million and a median of $21.0 million in 2025 define the central range for Non-Current Receivables.
  • Biggest five-year swings in Non-Current Receivables: crashed 93.25% in 2021 and later surged 4451.55% in 2023.
  • Year by year, Non-Current Receivables stood at $1.6 million in 2021, then crashed by 55.62% to $718150.0 in 2022, then surged by 4451.55% to $32.7 million in 2023, then soared by 36.97% to $44.8 million in 2024, then crashed by 53.03% to $21.0 million in 2025.
  • Business Quant data shows Non-Current Receivables for RDY at $21.0 million in Q1 2025, $44.8 million in Q1 2024, and $32.7 million in Q1 2023.